title: [Bone fracture receiving LH-RH agonists for prostatic cancer].
abstract: BACKGROUND
  Luteinizing hormone-releasing hormone (LHRH) agonists are popularly used drugs in the treatment of prostatic cancer. However, it has been reported that continuation of a low testosterone level following a longterm administration of these drugs reduces the bone mineral density and makes for osteoporosis, which is accountable for fracture, we measured the bone mineral density and bone metabolic markers in the cases who suffered fracture receiving LHRH agonists for prostatic cancer.
  
  
  METHODS
  Between 1994 and 1998, 196 patients (mean age 78.1 years) were treated with LHRH agonists for prostatic cancer. Of these patients, 13(7%) who had bone fracture during treated with LHRH agonists were divided into fracture group, and 70 patients who had not bone fracture divided into non-fracture group. Fracture by traffic accident was excluded. The bone density in the third lumbar vertebra was measured using quantitative computed tomography (QCT). Osteocalcin, 1, 25- (OH)2 vitamin D, urinary type 1 collagen cross-linked N-telopeptides (NTx), parathyroid hormone (PTH) and calcitonin were measured as bone metabolic markers.
  
  
  RESULTS
  The mean age of fractured cases was 78 years. The period from the start of treatment to fracture was 11 to 45 months (mean 27 months). No case of fracture at the site of metastasis of prostatic cancer was found. The bone density was significantly low in the fracture group compared with that of non-fracture group. Of the bone metabolic markers, NTx showed high values in the fracture group.
  
  
  CONCLUSIONS
  There is a need to measure bone mineral density and bone metabolic markers periodically and to evaluate secondary osteoporosis in the patients receiving LHRH agonists for prostatic cancer.
authors.affiliation: Department of Urology, Jikei University School of Medicine.
authors.forename: T
authors.initials: T
authors.lastname: Hatano
authors.forename: H
authors.initials: H
authors.lastname: Igarashi
authors.forename: J
authors.initials: J
authors.lastname: Nakada
authors.forename: Y
authors.initials: Y
authors.lastname: Oishi
authors.forename: S
authors.initials: S
authors.lastname: Yanada
authors.forename: A
authors.initials: A
authors.lastname: Furuta
authors.forename: A
authors.initials: A
authors.lastname: Takizawa
authors.forename: S
authors.initials: S
authors.lastname: Iwamuro
authors.forename: K
authors.initials: K
authors.lastname: Tashiro
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects*; D015519:Bone Density; D050723:Fractures, Bone / Q000139:chemically induced* / Q000175:diagnosis; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists*; D017273:Goserelin / Q000009:adverse effects*; D006801:Humans; D016729:Leuprolide / Q000009:adverse effects*; D008297:Male; D010024:Osteoporosis / Q000139:chemically induced* / Q000175:diagnosis; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D013131:Spine / Q000378:metabolism
chemical_list: D018931:Antineoplastic Agents, Hormonal; D017273:Goserelin; D007987:Gonadotropin-Releasing Hormone; D016729:Leuprolide